REGENERON PHARMACEUTICALS, INC. (REGN) Operating income 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) annual operating income history from SEC filings — each fiscal year as reported.
$3.6BFY2025 · since FY2016: $1.3B → $3.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.6B | -10.3% |
| FY2024 | $4.0B | -1.4% |
| FY2023 | $4.0B | -14.6% |
| FY2022 | $4.7B | -47.0% |
| FY2021 | $8.9B | +150.1% |
| FY2020 | $3.6B | +61.9% |
| FY2019 | $2.2B | -12.8% |
| FY2018 | $2.5B | +21.9% |
| FY2017 | $2.1B | +56.3% |
| FY2016 | $1.3B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More REGN financial trends
REGN RevenueREGN Net incomeREGN Net marginREGN Gross profitREGN Gross marginREGN Operating marginREGN Operating cash flowREGN Free cash flowREGN Capital expendituresREGN Return on equityREGN Stock buybacksREGN Dividends paidREGN Total assetsREGN Total liabilitiesREGN Shareholders’ equityREGN overview →